Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425331 | 0.85 | RELA (0.40) | NFE2L2RELAMAOBMAOA | |
| SCHEMBL26425329 | 0.84 | RELA (0.44) | NFE2L2RELAPTGS1PTGS2MAOB | |
| SCHEMBL26425440 | 0.83 | CA1 (0.63) | NFE2L2RELAPTGS1NQO2PTGS2 | |
| SCHEMBL26425328 | 0.83 | RELA (0.46) | NFE2L2RELAMAOBMAOAFBP1 | |
| SCHEMBL26425307 | 0.83 | NFE2L2 (0.52) | NFE2L2MAOBMAOAFBP1HRH4 | |
| SCHEMBL26425323 | 0.81 | RELA (0.54) | NFE2L2RELANQO2FBP1 | |
| SCHEMBL26425314 | 0.81 | PDE4B (0.38) | NFE2L2PTGS1NQO2CA1CA2 | |
| SCHEMBL26425338 | 0.80 | PDE4B (0.44) | PDE3AMAOBMAOAFBP1HRH4 | |
| SCHEMBL26425319 | 0.80 | PDE4A (0.41) | NFE2L2RELAPTGS1PTGS2CA1 | |
| SCHEMBL10053233 | 0.78 | CA1 (0.62) | CA1CA2PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | NFE2L2 2115/4885RELA 349/4885PTGS1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.